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Reproductive history in women with abdominal
aortic aneurysms
Christina Villard, MD,a,b Jesper Swedenborg, MD, PhD,a,b Per Eriksson, PhD,a and
Rebecka Hultgren, MD, PhD,a,b Stockholm, Sweden
Background: The prevalence of abdominal aortic aneurysms (AAAs) differs considerably between the sexes, illustrated by
the male/female ratio 4-6:1. Women are also reported to have a higher risk of rupture, and a poorer outcome compared
with men. The primary aim of this study was to investigate if women with AAA have a different reproductive history
compared with other women. The secondary aim was to study if women with a larger AAA differ in their reproductive
history from women with a smaller AAA.
Method: This case-control study was performed in October 2009 and included 140 consecutively monitored women with
AAA and 140 with peripheral arterial disease (PAD) at the Department of Vascular Surgery at Karolinska University
Hospital, Stockholm. AAAwas defined as AAA diameter>3 cm, and women with AAAwere subdivided into groups with
AAA diameter>5 cm and diameter<5 cm. A validated questionnaire was used to obtain information about participants’
reproductive history and general health. The response rate was 70% (n  196).
Results:Women with AAA were smokers to a greater extent than women with PAD (previous, 52% vs 46%; current, 46%
vs 34%, P .001). Diabetes mellitus was more prevalent in women with PAD (28%) than in women with AAA (15%, P
.034). Angina pectoris occurred more often in women with AAA (26%) than in women with PAD (11%, P  .026). No
significant difference was found between PAD and AAA women regarding statin use, treatment for hypertension, prior
myocardial infarction, and body mass index (BMI). The 54 women with AAA >5 cm and the 44 women with AAA <5
cm were similar in age (76 vs 76 years, P  .908) and BMI (25.7 vs 24.0 kg/m2, P  .66). No difference was noted in
the occurrence of other risk factors between women with AAA >5 cm and women with AAA <5 cm. Mean age at
menopause was lower in womenwith AAA>5 cm than in womenwith AAA<5 cm and in womenwith PAD (47.7 vs 49.9
vs 49.7 years, P  .011). Apart from menopausal age, the groups had a similar reproductive history, including hormone
replacement therapy, parity, use of contraceptives, prior gynecological surgery, and breast cancer.
Conclusion: These findings suggest that women with larger AAA reach menopausal age earlier, and this could influence an
earlier onset of aneurysmatic disease or an increase in aneurysm growth. The true role of endogenous estrogen in
aneurysm development and expansion is yet to be investigated. (J Vasc Surg 2011;54:341-5.)
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rAbdominal aortic aneurysm (AAA) is a condition ob-
served in an elderly population. The prevalence differs
considerably between the sexes, illustrated by the male/
female ratio 4-6:1.1 In addition to the difference in preva-
lence, women are reported to have a higher rupture risk,
and a poorer outcome compared with men.2-4
Most of the established risk factors found in patients
with AAA, including age, smoking, and high blood pres-
sure, coincide with known risk factors for atherosclerotic
disease,5 although the hereditary pattern and the male/
female ratio differ between the two patient groups.6,7 No
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e found in the literature.
The effects of female sex hormones on the cardiovas-
ular system in healthy and diseased women have been
nvestigated during the last decades.8 The incidence of
oronary artery disease (CAD) increases in women after
enopause,9 and lower estradiol levels earlier in life (hypo-
strogenemia) appear to be related to a higher risk for
remature CAD.10 However, expected positive effects of
ormone replacement therapy (HRT) on the risk for CAD
ave not been found in large randomized trials.11,12 The
ffects of estrogen on the vessel wall are intricate. Estrogen
ediates beneficial anti-inflammatory effects by direct an-
ioxidant effect, generation of nitric oxide, prevention of
poptosis, and suppression of cytokines.13 However, in the
ostmenopausal period with lower levels of female sex
ormones, HRT rather triggers adverse thrombotic and
roinflammatory effects.14,15
The positive effects of estrogen on aneurysm develop-
ent have been shown in animal studies. In rat elastase
odels, estradiol treatment inhibits the proteolytic activity
n the vessel wall and thereby protects rats from experimen-
al AAA formation.16,17 There is a lack of studies in humans
egarding a possible beneficial effect mediated by endoge-
ous estrogen on aneurysm development.
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JOURNAL OF VASCULAR SURGERY
August 2011342 Villard et alThe primary aim of this study was to investigate if
womenwith AAA have a different reproductive history than
women with an expected similar risk factor profile. The
secondary aim was to study if women with larger aneurysms
have a different reproductive history than women with
smaller AAA, as a surrogate marker for aneurysm disease
and growth.
METHODS
This study was approved by the local Ethics Committee.
Study population. A case-control study was per-
formed in October 2009, including 140 women with AAA
and 140 with peripheral arterial disease (PAD) consecu-
tively monitored at the Department of Vascular Surgery at
Karolinska University Hospital, Stockholm, between 2007
and 2010. Women with AAA were subdivided into two
groups: AAA diameter 5 cm and 5 cm. The measure-
ments of the aortic diameter were obtained from the last
ultrasound scan or computed tomography (CT) examina-
tion, which AAA patients undergo annually.
Women in the control group had had PAD, defined as
intermittent claudication with a walking distance 200
meters or ischemic rest pain with or without tissue loss, or
both. An ultrasound examination was offered to women in
the control group who had not undergone an imaging
examination, including the distal aorta during the last 4
years.
The participants were Caucasian women living in the
Stockholm area, with a catchment area covering 1.4 million
inhabitants. They were sent a questionnaire with 45 ques-
tions concerning general health and reproductive history.
The questionnaire was validated in 2004 in a study of
reproductive history in women with lower limb ischemia18
(Appendix, online only).
The general health questions focused on prior myocar-
dial infarction (MI), presence of angina pectoris, smoking
habits, body mass index (BMI), statin use, hypertension,
and diabetes mellitus. The questions about reproductive
history covered menarcheal age, prior use of contraceptive
medications, parity, menopausal age, HRT, prior gyneco-
logical surgery, and treatment for breast cancer. Women
who did not answer the questionnaire 2 months were
sent a reminder letter, and those who did not answer the
latter letter were contacted by telephone.
Twenty percent of the women’s questionnaires were
validated by comparing their answers regarding general
Table I. Patient characteristics: responders compared to n
AAA, mean (range)
Responders Nonrespon
Variable (n  98) (n  42
Age, years 76.0 (54-92) 79.5 (45-9
Aneurysm diameter, cm 4.9 (2.9-10.0) 5.0 (2.7-
AAA, Abdominal aortic aneurysm; PAD, peripheral arterial disease.health with data from their hospital records. All of their Atatements about comorbid conditions were in accordance
ith information from the hospital records.
Definitions. The variable hypertension was consid-
red fulfilled if the womenmedicated against the condition.
t the time of the study, patients with a pathological lipid
rofile were treated with statins, usually 20 to 40 mg of
imvastatin. Contraceptive therapy was defined as use of
irth control pills containing estrogen, progesterone, or
oth. Prior gynecologic operation was defined as hysterec-
omy, salpingo-oophorectomy, or both. HRT was defined
s the use of oral or exogenous hormone therapy against
enopausal symptoms.
Statistics. An a priori power analysis was performed to
etect the minimum number of participants required to
etect a significant difference, and 99 patients were re-
uired to detect a difference of 2 years in menopausal age
P  .05) at a power of 80%. However, we estimated a
issing cases frequency of at least 40% and therefore
dded this to the sample size. SPSS software (SPSS Inc,
hicago, Ill) was used for the statistical analyses. The
ndependent sample t test was applied for normally dis-
ributed continuous variables, and nonparametric Mann-
hitney or Kruskal-Wallis tests were applied for data
hat did not fulfill the assumption of normality. Differ-
nces for categoric and ordinal variables were assessed with
he 2 test. Differences were considered significant at the
evel .05.
Missing cases and exclusion criteria. The study ex-
luded 15 women in the control group who did not partic-
pate in the ultrasound examination. Seven women in the
AA group died during the course of this study, five before
aving answered the questionnaire. Two women with AAA
ied of aneurysm rupture. In total, 42 women in each
roup did not complete the study (Table I). The overall
esponse rate was 196 (70%; Fig).
ESULTS
Women with AAA were previous or current smokers to
greater extent than women with PAD (previous, 52% vs
6%; current, 46% vs 34%; P  .001). A larger proportion
f womenwith PADwere affected by diabetes mellitus than
ere women in the AAA group (28% vs 15%, P  .034;
able II). More women with AAA had angina pectoris
ompared with women with PAD (26% vs 11%, P .026).
here was no significant difference regarding statin use,
ypertension, prior MI, and BMI between women with
sponders
PAD, mean (range)
Responders Nonresponders
P (n  98) (n  42) P
.010 75.1 (50-91) 77.1 (51-92) .010
.688 . . . . . . . . .onre
ders
)
2)
8.6)AA and women with PAD.
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Volume 54, Number 2 Villard et al 343The mean age of the 54 women with AAA 5 cm and
the 44 women with AAA 5 cm was 76 years (P  .980).
The distribution of other risk factors, such as heredity for
AAA, BMI, prior MI, presence of angina pectoris, statin
use, hypertension, or diabetes mellitus did not differ be-
tween women with an AAA 5 cm and women with an
AAA 5 cm. Ninety-eight percent of women with both
AAA 5 cm and AAA 5 cm were former or current
smokers (P  .99).
Women with AAA 5 cm were approximately 2 years
younger at age for menopause than women with AAA 5
cm and women with PAD (Table III). The overall mean
duration of endogenous production of female sex hor-
mones (years between menarche and menopause) was
Fig. Study flow chart. AAA, Abdominal ao
Table II. Patient demographics
Variablea
PAD AAA
P(n  98) (n  98)
Age, years 75.1 (50-91) 76.0 (54-92) .67
AAA diameter, cm 4.9 (2.9-10.0)
Smoking
Never 18 (19) 2 (2)
Prior 43 (46) 50 (52) .001
Current 32 (34) 44 (46)
Hypertension 73 (80) 65 (73) .292
Statin use 70 (75) 67 (73) .739
BMI, kg/m2 25.2 (16-35) 24.9 (14-36) .778
CAD
Angina pectoris 10 (11) 20 (26) .026
Prior MI 16 (17) 24 (26) .156
Diabetes mellitus (%) 27 (28) 14 (15) .034
Heredity for AAA 6 (15) 22 (28) .739
AAA, Abdominal aortic aneurysm; BMI, body mass index; CAD, coronary
atherosclerotic disease; MI, myocardial infarction.
aData are presented as mean (range) or number (%).lower in women with AAA 5 cm than in women with hAA 5 cm or PAD (33.9 vs 36.4 and 36.7 years, P 
003). This difference is caused by the earlier onset of
enopause in women with larger AAAs.
ISCUSSION
Women with AAA 5 cm have shorter lifetime dura-
ion of endogenous sex hormone production than women
ith AAA 5 cm or women with PAD. Furthermore, the
isk factor profile in women with AAA differs somewhat
rom women with PAD, with a higher frequency of smok-
ng and angina but fewer with diabetes mellitus.
To our knowledge, this is the first study to examine a
ossible altered reproductive history in women with AAA
ompared with women without AAA. The results suggest
hat a shorter period of sex hormone production, as a
onsequence of lower menopausal age, could be a contrib-
ting explanation for an earlier development of disease or
ncreased growth rate. Owing to the apparent difficulty in
stimating when aneurysm formation begins, it is difficult
o value whether women with larger AAAs develop the
neurysm at a younger age or have an increased growth
ate. The observation that womenwith AAA5 cm did not
iffer from women with AAA 5 cm regarding the estab-
ished risk factors for AAA development and growth, in-
luding smoking habits, age, and heredity,19,20 further
trengthen an association between menopausal age and
neurysm size.
The menopausal age for women with PAD and women
ith AAA 5 cm in this study is similar to the 49.9 years
bserved in Sweden for smokers in the corresponding birth
ohorts. Smoking affects ovarian function,21 illustrated by
he approximately 1.44 years lower menopausal age in
moking women.22 Other predisposing factors affecting
enopausal age are late menarcheal age, BMI, parity, and
neurysm; PAD, peripheral arterial disease.eritability of menopausal age.22,23
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August 2011344 Villard et alNeither smoking habits, a strong predictor for aneu-
rysm development and growth,24 nor menarcheal age, par-
ity, and BMI differed significantly between the womenwith
AAA 5 cm vs AAA 5 cm. These factors can conse-
quently be excluded as alternative explanations for the
lower menopausal age in women with AAA 5 cm.
If women with AAA have a shorter duration of endog-
enous hormone production, as our findings suggest, it
would be of interest to value whether exogenous estrogen,
for instance HRT, could affect the development of AAA, as
illustrated in animal models where estradiol treatment in-
hibited aneurysm formation.25 However, we could find no
significant association between the occurrence of AAA and
HRT. A negative correlation was reported between AAA
occurrence and HRT, if the women had taken HRT for5
years.26 Another study reported a higher frequency of AAA
in women treated with conjugated equine estrogens.27
The occurrence of breast cancer and prior gynecologi-
cal surgery did not differ between the groups, whichmay be
explained by the low occurrence of these conditions in the
study. All women in the study who had undergone gyne-
cological surgery had already reached menopausal age,
which might be an explanation for the lack of a significant
association between AAA and a past gynecological surgery
(ie, iatrogenic-induced estrogen deficiency).
More women with AAA had angina pectoris than
women with PAD in our study, verifying prior studies
where women with AAA were reported to have a high
occurrence of CAD.28,29 The occurrence of diabetes mel-
litus was higher in women with PAD than in women with
AAA, confirming earlier studies in men, where diabetes
mellitus was found to be negatively associated with AAA
occurrence.30 A plausible explanation might be the calcifi-
cation and loss of compliance caused by the macroangiopa-
thy, which is associated with the condition.31
The association between smoking and AAA is well
known.32 A similar association is verified for the pathology
of PAD.33 Current smoking has been observed to be more
strongly related to AAA occurrence in women than in
men.34 The even more pathological smoking habits found
in women with AAA compared with women with PAD in
this study suggest smoking is a contributing factor to
Table III. Reproductive history in women with periphera
5 cm and AAA 5 cm
PAD
Variablea (n  98)
Age, years 75 (50-91
Menarcheal age, years 13.5 (10-17
Use of contraceptives 37 (45)
Parity, number 2.3 (0-9)
Menopausal age, years 49.7 (31-67
Endogenous hormone production, years 36.7 (19-54
Hormone replacement therapy 48 (49)
Prior gynecological surgery 21 (23)
Breast cancer 3 (3)
aData are presented as mean (range) or number (%).consider regarding aneurysm development in women.We acknowledge that there are limitations with this
elf-reported inquiry. There is always a problem with a
arying number of nonresponders, although the response
ate was very satisfactory in this study.
There might be recall bias due to the number of years
aving passed since some of the events. It is, however, most
nlikely that this bias would influence the groups with AAA
nd PAD differently. The higher mean age among nonre-
ponders could theoretically have affected the risk factor
rofile, differing from the somewhat younger women com-
leting the study. It should be noted that the nonre-
ponders had a similar aneurysm size, which indicates that
his limitation is less important.
ONCLUSIONS
The findings suggest that women with larger AAA
ore frequently have had an earlier menopause, and this
ould influence an earlier onset of aneurysmatic disease or
ncreased aneurysm growth. The true role of endogenous
strogen in aneurysm development and expansion is yet to
e investigated.
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Name: _____________________________________.
Married □ Unmarried □ Widow □ Divorced □ Significant other □
Highest level of education: compulsory school □ upper secondary school education □ university education □
Retired: yes □ no □
Weight: _______________
Height: _______________
Vascular disease
1) Have you ever gone through a surgical operation due to reduced blood flow in blood vessels?
yes □ no □ don’t know □
If your answer is NO or DON’T KNOW proceed to question number 4.
What symptoms did you have that led to treatment at Karolinska University Hospital?
a) Pain in your foot/leg while walking: yes □ no □ don’t know □
b) Pain in your foot/leg during the night, preventing sleep: yes □ no □ don’t know □
c) Ulcers that would not heal on your foot/leg: yes □ no □ don’t know □
3) For how long did you have symptoms before getting treatment? __________
4) Do you have an abdominal aortic aneurysm? yes □ no □ don’t know □
If your answer is NO or DON’T KNOW proceed to question number 9.
5) Do you have any siblings, parents or children that have had an abdominal aortic aneurysm?
yes □ no □ don’t know □
6) Do you have any siblings, parents or children that have had a thoracic aortic aneurysm?
yes □ no □ don’t know □
7) How many affected siblings, parents or children are there in your family? 0 □ 1 □ 1 □
8) How is/was this person related to you? father □ mother □ brother □ sister □ child □
. . . . or a more distant relative? cousin □ grandfather □ grandmother □ other □ _________
Heart disease
9) Have you had a heart attack? yes □ no □ don’t know □
10) Do you have angina/chest pain? yes □ no □ don’t know □
Diabetes
11) Do you have diabetes? yes □ no □ don’t know □
If your answer is NO or DON’T KNOW proceed to question number 14.
12) How is your diabetes treated?
a) Diet: yes □ no □ don’t know □
b) Oral medication: yes □ no □ don’t know □
c) Syringes adjacent to meals: yes □ no □ don’t know □
13) For how long have you been treated for diabetes? _______
Lipids
14) Have you been treated for elevated lipids? yes □ no □ don’t know □
If your answer is NO or DON’T KNOW proceed to question number 16
15) How is/was the elevated lipids treated?
a) Diet: yes □ no □ don’t know □
b) Oral medication: yes □ no □ don’t know □
Smoking
16) Do you smoke? yes □ no □
If your answer is NO proceed to question number 17.
a) How many cigarettes do you smoke daily? _______
b) For how many years have you been smoking? _____
17) Have you smoked? yes □ no □
If your answer is NO proceed to question number 18.
a) How many cigarettes did you smoke daily? _______
b) For how many years did you smoke? _______
JOURNAL OF VASCULAR SURGERY
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18) When did you have your last gynecological examination? ____
19) What was the result?
a) Normal conditions: yes □ no □ don’t know □
b) Dryness: yes □ no □ don’t know □
c) Cysts in the ovaries: yes □ no □ don’t know □
d) Myomas in the uterus: yes □ no □ don’t know □
e) Something else __________
20) How old were you when you had your first menstruation? __________
21) How many times have you had children? ________
22) Have you ever taken oral contraceptives? ________
23) When did you use them? __________
24) Please name them __________
25) Have you taken medicines containing progesterone (i.e., mini-pills)? yes □ no □
26) When did you use them? __________
27) Please name them __________
28) Have you ever used an estrogen intrauterine device (for example Levonova)? yes □ no □ don’t know □
29) Have your menstruations stopped? yes □ no □ don’t know □
30) How old were you when you had your last menstruation? __________
31) Have you ever used female sex hormones, i.e. estrogen or progesterone orally? yes □ no □ don’t know □
32) Have you ever used female sex hormones (i.e., estrogen and/or progesterone as plasters)?
yes □ no □ don’t know □
33) Have you ever used female sex hormones, i.e. estrogen and/or progesterone as local therapy?
yes □ no □ don’t know □
If your answer is NO or DON’T KNOW to questions 31-33 proceed to question number 38.
34) Why did you receive this treatment?
a) Menopausal problems yes □ no □ don’t know □ (sweating, mood swings)
b) Urinary tract problems yes □ no □ don’t know □
c) Dryness yes □ no □ don’t know □
d) Against osteoporosis yes □ no □ don’t know □
e) Something else _____________
35) Which doctor prescribed this therapy? gynecologist □ general practitioner □ other _________
36) Please name the pill or plaster that you used ________________________________
37) For how long have you had this treatment? ________________________________
38) Have you gone through gynecological surgery? yes □ no □ don’t know □
If your answer is NO or DON’T KNOW proceed to question number 42.
39) What sort of operation did you go through?
a) Removing the uterus: yes □ no □ don’t know □
b) Removing the ovaries: yes □ no □ don’t know □
40) How old were you when you had the operation? __________
41) Was the operation part of a treatment against cancer? yes □ no □ don’t know □
42) Have you been treated for breast cancer? yes □ no □ don’t know □
If your answer is NO or DONT’T KNOW proceed to question number 45, last question,
43) What treatment did you go through? surgery □ radiation □ chemotherapy □
44) Has the treatment ceased? yes □ no □ don’t know □
45) Please name the medicines and how many tablets that you take daily
____________________________________________
____________________________________________
____________________________________________
____________________________________________
Thank you!
